Risperidone augmentation in treatment-resistant obsessive–compulsive disorder: a double-blind, placebo-controlled study
This double-blind, placebo-controlled trial was performed to determine the efficacy and tolerability of 8 wk of risperidone augmentation of serotonin reuptake inhibitor (SRI) treatment in adult subjects with treatment-resistant obsessive–compulsive disorder (OCD) (failure of at least two SRI trials). Sixteen adult treatment-resistant OCD patients were randomly assigned to augmentation with 8 wk of either risperidone (n=10) (0.5–3.0 mg/d) or placebo (n=6) following at least 12 wk of SRI treatment. Four patients on risperidone (40%) and none (0%) on placebo were responders with both a Clinical Global Impression – Improvement (CGI-I) score of 1 or 2 and a Yale–Brown Obsessive–Compulsive Scale (Y-BOCS) decrease [gt-or-equal, slanted]25%. Risperidone was generally well tolerated: there were 3 dropouts, 1 on risperidone and 2 on placebo. Better Y-BOCS insight score at baseline significantly correlated with a greater CGI-I score at endpoint on risperidone augmentation. Risperidone may be an effective and well-tolerated augmentation strategy in treatment-resistant OCD subjects, but larger sample size studies are required to demonstrate this.(Received August 26 2002)
(Reviewed December 22 2002)
(Revised May 13 2003)
(Accepted May 18 2003)
Key Words: Compulsions; obsessions; obsessive–compulsive disorder; risperidone; treatment resistant.
c1 Dr E. Hollander, Department of Psychiatry, Box 1230, Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY 10029, USA. Tel.: 212-241-3623 Fax: 212-987-4031 E-mail: [email protected]